Domperidone in the Treatment of Dyspepsia: A Double-Blind Placebo-Controlled Study
- 1 March 1979
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 7 (2) , 158-161
- https://doi.org/10.1177/030006057900700208
Abstract
Domperidone, at a dosage of 20 mg t.d.s. before meals, in a double-blind, crossover, placebo-controlled trial reduced the level of the symptoms of dyspepsia by 76% compared to a 16% reduction with placebo. This difference was statistically significant (p <0·001). Thirteen of the fourteen patients in the study preferred domperidone to placebo. Four patients in the active treatment period and one in the placebo complained of mild side-effects.This publication has 4 references indexed in Scilit:
- DOMPERIDONE, A NOVEL GASTROKINETIC AND ANTI-NAUSEANT DRUG, INTERACTS SELECTIVELY WITH DOPAMINE RECEPTORSPublished by Elsevier ,1978
- ARE THE GASTROKINETIC PROPERTIES OF DOMPERIDONE RELATED TO DOPAMINE AND SECRETIN ANTAGONISM IN THE GASTRIC WALL?Published by Elsevier ,1978
- Dopamine as A Possible Neurotransmitter in Gastric RelaxationGastroenterology, 1976